Is Inogen, Inc. overvalued or undervalued?

As of 24 February 2022, Inogen, Inc. has moved from an attractive to a risky valuation grade. The company is currently considered overvalued, given its negative earnings and poor financial ratios. Notably, the P/E ratio is not applicable due to losses, while the Price to Book Value stands at 0.90, indicating that the stock is trading below its book value. The EV to EBITDA is -5.76, and the ROCE is a concerning -39.46%, highlighting significant operational inefficiencies.
In comparison with peers, Inogen's valuation metrics are unfavorable. For instance, Butterfly Network, Inc. has an EV to EBITDA of -6.90, while Bioventus, Inc. shows a P/E ratio of 327.43, indicating a stark contrast in performance. The recent stock performance has been poor, with a year-to-date return of -27.26%, significantly underperforming the S&P 500, which has returned 2.44% in the same period. Overall, these factors suggest that Inogen, Inc. is overvalued in its current market position.